Zenas BioPharma, Inc.
ZBIO · Nasdaq · USD · Market cap $1.7B · 167 employees
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price23.85 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $32.00 to $50.08, base estimate $46.50 (screen dated 2026-11-20).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-20
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Zenas BioPharma, Inc. holds its Accumulation at $23.85. Consolidating, no directional conviction, held for 68 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 68 days |
| Price at the screen | $23.85 |
| Valuation | N/A trailing · -5.20 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | -0.86 |
Five Screens: ZBIO's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.35% | Below 33% | Pass |
| Interest-bearing cash | 60.62% | Below 33% | Fail |
| Receivables | 28.84% | Below 49% | Pass |
| Revenue purity | 100.00% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Zenas BioPharma,'s business is fine, but its cash and interest-bearing securities are about 61% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when ZBIO's ethical verdict changes
Today ZBIO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 49% discount to our $46.50 fair value.
USD, 2026-11-20 screen. A 48.7% under base.
Street: 8 covering, consensus Strong Buy. Average target +95%.
Biotech bet with no financials to judge
Picture a lab team betting everything on one antibody still in early trials. Zenas BioPharma offers exactly that, a clinical stage immunology programme with zero revenue and no profit margin to show for it. Analysts like the story enough for a strong buy call and a forty four dollar median target, yet our screen returns insufficient data and no opportunity rating at all.
The reported numbers underline the gap. Forward earnings sit at minus thirteen times, return on equity runs at minus one hundred thirty seven percent, and the company has yet to clear the basic financial ratios we check. Without those anchors any margin of safety calculation remains guesswork even when the share price sits well below our internal fair value line.
Risk here is therefore unquantifiable on standard metrics. Currency, dilution and trial failure sit on top of the ethical data shortfall. We pass until the figures arrive. Analysis, not advice.
| Forward P/E | -5.2x |
| EPS, trailing | -10.08 |
| EPS, forward | -4.82 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -265.1%not currently earning a positive return on equity |
| FCF yield | -14.76% |
| Debt to equity | 1.42a meaningful debt load worth watching |
| Current ratio | 9.42comfortably covers its short-term bills |
| Beta | -0.86barely tracks the market's swings |
| Short interest, float | 0.24% |
| 52-week range | 13.50 - 44.60 |
| Market cap | $1.7B |
| Employees | 167 |
ZBIO-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Earnings landed in this window.
The framework has shifted from markdown to accumulation since the last review.
The framework has shifted from accumulation to markdown since the last review.
The framework has shifted from markup to accumulation since the last review.
The framework has shifted from accumulation to markup since the last review. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference Yahoo Finance · 12d ago
- Zenas BioPharma (ZBIO) After Third Quarter Losses Still Carries An Undervalued Narrative Yahoo Finance · 14d ago
- Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update Yahoo Finance · 16d ago
- Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears Yahoo Finance · 22d ago
- Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know Yahoo Finance · 29d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $20.40 | -12.2% | · | $878 | -12.2% |
| 2 months | $20.44 | -12.4% | · | $876 | -12.4% |
| 3 months | $24.50 | -26.9% | · | $731 | -26.9% |
| 6 months | $40.21 | -55.5% | · | $445 | -55.5% |
| 1 year | $11.94 | +50.0% | · | $1,500 | +50.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ZBIO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.